Does the Body Get Used to It? GLP-1 Tolerance, Receptor Desensitisation, and the Plateau

Around month four something shifts. The queasiness after dinner that used to end the meal for you has gone quiet. Food sits differently. Nothing about the dose has changed, and the obvious conclusion arrives on its own: the body has adapted, the medication is wearing off, and the number on the scale is about to prove it.

That conclusion is half right in a way that matters. GLP-1 receptor agonists do lose one of their effects with continued exposure, and the loss is measurable, reproducible, and documented in humans within hours rather than months. The effect that fades is the delay in gastric emptying. The effect people actually rely on, the reduction in appetite and food noise, behaves very differently, and the long trials show it holding for a year and beyond. Reading a fading side effect as a fading drug is one of the most common misinterpretations in this space, and it drives dose escalations that were never needed.

This article separates four things that everyday conversation collapses into the single word tolerance: receptor desensitisation at the cell surface, tachyphylaxis of a specific physiological effect, the energy balance plateau that arrives around a year in, and neutralising anti-drug antibodies. They have different mechanisms, different timelines, and very different implications for what you should do next.

Does the body build a tolerance to GLP-1 medications?

To one effect, quickly and predictably. To the rest, much less than people assume. The clearest human evidence comes from work by Nauck and colleagues published in Diabetes in 2011, which examined what happens to the gastric emptying effect during continuous GLP-1 exposure. The deceleration of gastric emptying that GLP-1 produces on first exposure was substantially blunted when the exposure was maintained. This phenomenon has a specific name, tachyphylaxis, which describes rapid attenuation of a drug response with repeated or sustained administration.

Tachyphylaxis of gastric emptying is the reason nausea, early fullness, and the sense that food is sitting in the stomach all tend to be worst in the first weeks of a protocol and after every dose increase, then settle. Clinicians count on it. It is also the reason a person four months in can honestly report that the medication feels weaker while their appetite is still substantially reduced, because the sensation they were tracking was never the appetite effect in the first place.

What is receptor desensitisation, and does it happen in people?

Receptor desensitisation is the cell pulling receptors off its own surface after prolonged stimulation, and it is well demonstrated for the GLP-1 receptor in laboratory systems. The GLP-1 receptor belongs to the class B family of G protein coupled receptors. When an agonist binds and stays bound, the receptor is phosphorylated, beta-arrestin is recruited, and the receptor is internalised into the cell where it is either recycled back to the surface or routed for degradation. A cell with fewer surface receptors responds less to the next dose of the same signal.

The most persuasive demonstration that this matters came from Jones and colleagues in Nature Communications in 2018. Their group engineered an exendin analogue with reduced beta-arrestin recruitment and slower internalisation, and it produced greater prolonged insulin secretion and better glucose lowering in mice than the parent compound, despite being a weaker agonist by conventional measures. Trafficking, in other words, was a bigger lever on sustained effect than raw potency was. Buenaventura and colleagues extended the same picture of GLP-1 receptor trafficking in beta cells.

The honest limit is the translation gap. Receptor internalisation is measured in cells and rodents over minutes and hours. Human weight loss trials run for a year or more and do not measure surface receptor density in anyone. So the mechanism is solid and the clinical magnitude is unresolved, which is a very different thing from saying tolerance has been proven in patients.

Which GLP-1 effects fade, and which ones hold?

Gastric effects fade substantially, appetite and glycaemic effects largely hold. That split is the single most useful thing to carry out of the tolerance question, because it tells you how to interpret your own experience. A person whose nausea has vanished has not lost their appetite suppression, and a person whose glucose readings are stable has not lost receptor sensitivity in the pancreas.

The persistence of the appetite effect is visible in the trial durations themselves. STEP 1 ran 68 weeks on a fixed maintenance dose and the treatment group ended at a mean 14.9 percent below baseline weight, a figure that would be impossible if appetite suppression had collapsed at month four. SURMOUNT-1, reported by Jastreboff and colleagues in the New England Journal of Medicine in 2022, ran 72 weeks with tirzepatide and reached a mean 20.9 percent reduction at the highest dose. Neither curve looks like a drug that stopped working.

Central signalling is the likely reason for the difference. The appetite effect is driven substantially through GLP-1 receptor populations in the hypothalamus and hindbrain, which Kanoski and colleagues mapped in their review of the neural circuitry, and those circuits appear less prone to the rapid desensitisation seen in the gut motility pathway. Different receptor populations, different adaptation timelines, same molecule.

Why does weight loss plateau around month twelve?

The plateau is arithmetic before it is pharmacology. A body that has lost 15 percent of its mass carries less tissue to maintain, moves that smaller mass at lower cost, and therefore burns fewer calories doing exactly what it did before. On top of that sits adaptive thermogenesis, the phenomenon Leibel and colleagues documented in the New England Journal of Medicine in 1995, where resting energy expenditure after weight loss falls below what body composition alone predicts. The deficit that produced steady loss at month two has quietly become maintenance by month twelve.

Counter-regulatory signalling adds a second layer. Weight loss raises ghrelin and lowers leptin, which increases hunger drive against a medication that is still suppressing it. The net appetite signal a person experiences is the difference between two forces, and the opposing force grows as weight falls. Nothing about the receptor has to change for the felt effect to weaken.

Where the plateau lands differs by agent and by dose. STEP 1 flattened around week 60 with semaglutide 2.4 mg. SURMOUNT-1 continued to descend later into its 72 weeks with tirzepatide, which is consistent with a dual GIP and GLP-1 mechanism producing a larger total effect rather than a slower adaptation. Both curves eventually flatten, because every weight loss curve eventually flattens.

Do anti-drug antibodies stop the medication working?

Antibodies form often with some agents and rarely change the outcome. The pattern tracks molecular origin. Exenatide is derived from exendin-4, a lizard peptide with limited homology to human GLP-1, and it provoked treatment-emergent antibodies in a large share of users across its development programme, with high titres linked to attenuated glucose lowering in some analyses. Semaglutide and liraglutide are built on the human GLP-1 backbone, and their antibody rates are far lower.

Across the SUSTAIN programme, treatment-emergent anti-drug antibodies to semaglutide were detected in roughly 1 percent of participants and were not associated with reduced efficacy or with a distinct safety signal. Tirzepatide is the interesting exception, with treatment-emergent antibodies reported in around half of participants in the SURPASS programme but neutralising antibodies in a small minority and no clear relationship to glycaemic or weight outcomes. A high antibody rate and a high failure rate are not the same finding.

For someone whose effect changed abruptly, antibodies are near the bottom of the list of explanations worth checking. Degraded product from a broken cold chain, a reconstitution error that changed the actual delivered dose, injection into scar tissue or lipohypertrophy, and a newly added medication all sit far above it in likelihood and are all easier to verify.

Does microdosing change the desensitisation picture?

No trial has answered this, and anyone who tells you otherwise is ahead of the evidence. What exists is a mechanistic argument with one genuinely interesting human study behind it. Umapathysivam and colleagues, writing in Diabetes in 2014, compared prolonged and intermittent stimulation of the GLP-1 receptor and found that the slowing of gastric emptying was preserved under intermittent stimulation while it waned under prolonged stimulation. Exposure pattern, not just exposure amount, changed whether the effect survived.

Laid alongside the receptor trafficking work, that finding has an obvious extrapolation: lower and less saturating receptor occupancy should produce less internalisation and less desensitisation. The extrapolation is reasonable. It is also entirely untested at the doses microdosing protocols use, in the outcomes that matter to people taking them, over the timeframes anyone actually cares about. Describing it as a demonstrated advantage of microdosing would be a claim the data does not support.

There is a further complication worth naming. Long-acting agents such as semaglutide were engineered specifically for sustained plasma exposure, with a half-life near one week, so a weekly microdose is still continuous exposure at a lower concentration rather than genuinely intermittent stimulation. Whether concentration or pattern is the variable that governs desensitisation in humans is an open question, and it is the question a proper trial of microdosing would need to answer.

What should you do when the effect seems to be fading?

Work out which effect changed before changing anything else. Fading nausea alongside intact appetite control is the expected trajectory and needs no intervention. Slowing weight loss after nine to fourteen months on an unchanged dose is a plateau, and the response that fits it is protein intake, resistance training, and patience rather than more medication. Genuine loss of appetite control after a long stable period is the only pattern that points at the drug itself, and it is the least common of the three.

Before concluding anything about biology, check the boring explanations. Compounded product that spent a weekend above refrigeration temperature, a reconstitution volume that was miscalculated, repeated injection into the same site, and a syringe with graduations you have been reading approximately will each produce a real drop in delivered effect. These are also the explanations you can verify without a laboratory.

Deliberate drug holidays deserve particular caution. The idea that a break resets receptor sensitivity is untested in this class, and the withdrawal data runs against it. Wilding and colleagues reported in Diabetes, Obesity and Metabolism in 2022 that participants in the STEP 1 extension regained about two thirds of their lost weight within a year of stopping semaglutide, with cardiometabolic improvements reverting in step. Stopping to chase a reset has a known cost and an unknown benefit. Every dosing decision here belongs with the prescriber who can see your labs and your history.

The word tolerance is doing too much work

Four separate phenomena hide inside one word, and they call for four different responses. Tachyphylaxis of gastric emptying is real, fast, and mostly welcome. Receptor desensitisation is well demonstrated in cells and unresolved in people. The energy balance plateau is physics catching up with a smaller body. Neutralising antibodies are rare enough to sit last on the list. Someone who can tell those apart in their own experience will make better decisions than someone reaching for a dose increase because the medication stopped feeling like anything.

Frequently asked questions

Clinical references

1. Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes. 2011;60(5):1561-1565.
2. Umapathysivam MM, Lee MY, Jones KL, et al. Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia. Diabetes. 2014;63(2):785-790.
3. Jones B, Buenaventura T, Kanda N, et al. Targeting GLP-1 receptor trafficking to improve agonist efficacy. Nature Communications. 2018;9(1):1602.
4. Buenaventura T, Bitsi S, Laughlin WE, et al. Agonist-induced membrane nanodomain clustering drives GLP-1 receptor responses in pancreatic beta cells. PLOS Biology. 2019;17(8):e3000097.
5. Roed SN, Wismann P, Underwood CR, et al. Real-time trafficking and signaling of the glucagon-like peptide-1 receptor. Molecular and Cellular Endocrinology. 2014;382(2):938-949.
6. Fletcher MM, Halls ML, Christopoulos A, Sexton PM, Wootten D. The complexity of signalling mediated by the glucagon-like peptide-1 receptor. Biochemical Society Transactions. 2016;44(2):582-588.
7. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384(11):989-1002.
8. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022;24(8):1553-1564.
9. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205-216.
10. Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. 2021;385(6):503-515.
11. Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. New England Journal of Medicine. 1995;332(10):621-628.
12. Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. New England Journal of Medicine. 2011;365(17):1597-1604.
13. Kanoski SE, Hayes MR, Skibicka KP. GLP-1 and weight loss: unraveling the diverse neural circuitry. American Journal of Physiology, Regulatory, Integrative and Comparative Physiology. 2016;310(10):R885-R895.
14. Jalleh RJ, Rayner CK, Hausken T, et al. Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions. Lancet Gastroenterology and Hepatology. 2024;9(10):957-964.
15. Fineman MS, Mace KF, Diamant M, et al. Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment. Diabetes, Obesity and Metabolism. 2012;14(6):546-554.
16. Chao P, Cui X, Wang S, et al. Immunogenicity of glucagon-like peptide-1 receptor agonists: a review of the clinical evidence. Diabetes Therapy. 2023;14(2):233-249.